Anti-Coronavirus Therapy (ACT) to prevent COVID-19 disease progression: a clinical trial platform
- Funded by Canadian Institutes of Health Research (CIHR)
- Total publications:0 publications
Grant number: 172627
Grant search
Key facts
Disease
COVID-19Start & end year
20202020Known Financial Commitments (USD)
$2,202,839.25Funder
Canadian Institutes of Health Research (CIHR)Principal Investigator
Sonia Savitri Anand, Alvaro Avezum, Shrikant I Bangdiwala, Emilie Prudence Belley-Côté, Noel Chan, Shurjeel Choudhri, Antonio Limcaco Dans, Rafael Diaz, John Wa Eikelboom, Michael Eand Camilo Farkouh, Hertzel C Felix, Jeff Sean Gerstein, Sanjit Singh Healey, Darryl Jolly, Mark Bertram Leong, Jose Patricio Loeb, Guillaume Lopéz, Richard Paré, Salim Whitlock…Research Location
CanadaLead Research Institution
McMaster University MedicineResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Clinical trial (unspecified trial phase)
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Controlled Clinical Trial
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
COVID-19 has been diagnosed in millions of persons and has caused several hundred thousand deaths. Effective treatments are urgently required. We have created the "Anti-Coronavirus Therapies (ACT) to prevent COVID-19 disease progression" trials platform to rapidly evaluate whether several commonly available interventions can be repurposed for the treatment of COVID-19 disease. The specific aims of our research are to determine whether treatments that: (a) reduce the levels of virus in the body, (b) reduce the response by the body to the infection (i.e., inflammation), and (c) prevent blood clotting can prevent COVID-19 disease progression. We will test these treatments alone and in combination in two trials: (1) Outpatient trial: here we are trying to patients diagnosed with COVID-19 from needing to go to hospital. (2) Inpatient trial: here we are trying to prevent patients with COVID-19 who are already hospitalized from being admitted to the intensive care unit and from dying. The trial started in Canada on April 21 and will eventually include about 4,000 patients from at least 100 centres and at least 12 countries around the world.